BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 11041454)

  • 1. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
    Mazzaferri EL; Kloos RT
    Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.
    Mazzaferri EL; Massoll N
    Endocr Relat Cancer; 2002 Dec; 9(4):227-47. PubMed ID: 12542401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.
    Bombardieri E; Seregni E; Villano C; Aliberti G; Mattavelli F
    Tumori; 2003; 89(5):533-6. PubMed ID: 14870779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
    Perros P
    J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
    Schlumberger MJ; Incerti C; Pacini F; Reiners C
    J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
    Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
    Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.